Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Wenxue Ma

Photo of Wenxue Ma
Title(s)Project Scientist, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
Emailwma@ucsd.edu
ORCID ORCID Icon0000-0001-9228-6162 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California-San Diego, San Diego, CAPostdoc04/2005Cancer Immunotherapy
    University of Wisconsin-Madison, Madison, WIPostdoc08/2004Molecular Immunology
    University of Nebraska Medical Center, Omaha, NEPostdoc08/2002Drug Delivery with Nanotechnology
    Zhejiang University, HangzhouPhD06/2002Immuno-Oncology
    Zhejiang Medical University, HangzhouMS07/1997Clinical Oncology
    Zhejiang Medical University, HangzhouMD07/1989Clinical Medicine
    Collapse awards and honors
    Cytokine & Growth Factor Reviews 2025  - PresExecutive Guest Editor
    Frontiers in Immunology2022  - PresAssociate Editor
    Frontiers in Oncology2022  - PresAssociate Editor
    European Science Foundation (ESF)2023  - PresGrant Review Expert
    Research Foundation Flanders (FWO)2023  - PresGrant Review Expert
    INSERM (French National Institute of Health and Medical Research)2025  - PresGrant Evaluation Expert
    Discover Oncology2024  - PresEditorial Board Member
    World Journal of Clinical Oncology 2024  - PresEditorial Board Member
    Royal Society of Medicine (RSM)2024  - PresFellow Member
    Oncology Research2022  - PresEditorial Board Member
    Oncology Advances2022  - PresEditorial Board Member
    Oncology Research2022  - 2024Guest Editor
    Cancers2022  - 2023Guest Editor
    Natural Science Foundation of Zhejiang, China2014  - 2017Identification & application of novel survivin antigenic peptide sequences. PI (LY14H160015)
    Huzhou University School of Medicine, China2012  - 2014Dean & Distinguished Professor
    American Association for Cancer Research2010  - 2010AACR Scholar-in-Training Award
    International Society for Stem Cell Research2010  - 2010ISSCR Travel Award
    Geron Corporation2007  - 2008Induction of telomerase-specific cytotoxic T lymphocytes (Geron/28-1075), PI (WM001)
    Zhejiang University, China2000  - 2001Outstanding Postgraduate Scholarship
    Zhejiang University, China2000  - 2001Hisun Pharmaceutical Scholarship
    Zhejiang University, China2000  - 2001The First-class Scholarship
    Zhejiang University, China1999  - 2000Tiwu Wang Scholarship

    Collapse Overview 
    Collapse overview
    🏥 I am a board-certified Attending Surgical Oncologist with PhD degree, currently serving as the Director of Drug Discovery at the Sanford Stem Cell Institute, University of California, San Diego.

    🔬 My research expertise spans cancer immunotherapy, cancer stem cells (CSCs), and nanomedicine: In cancer immunotherapy, I focus on enhancing immune responses to target malignant cells. In the field of cancer stem cells, I develop targeted therapies such as Notch1 oncogene-based treatments for leukemia and investigate the role of the ADAR1 p150 isoform in leukemia-initiating cell (LIC) generation. I lead the development of Rebecsinib, a selective small-molecule inhibitor of splicing-mediated ADAR1 activation, which inhibits leukemia stem cell (LSC) self-renewal and prolongs survival in humanized LSC mouse models. In Nanomedicine, I advance nanotechnology-based drug delivery systems, including innovative peptide-based platforms for targeted therapeutic delivery.

    🎓 I previously served as Dean and Distinguished Professor at the School of Medicine, Huzhou University, where I led strategic efforts that successfully elevated the Clinical Medicine Recruitment Program from second-tier to first-tier status.

    📝 I hold several editorial positions, including: Associate Editor for Frontiers in Immunology and Frontiers in Oncology; Guest Editor for Cancers, Oncology Research; Editorial Board Member (EBM) for Oncology Research, Discover Oncology, Oncology Advances, and the World Journal of Clinical Oncology.

    🧪 I have served as a peer reviewer for 82 medical science-related journals since 2006.
    Since January 2023, I have been a grant reviewer for the European Science Foundation (ESF) and the Research Foundation Flanders (FWO), and since March 2025, I have served as a grant evaluation expert for the French National Institute of Health and Medical Research (INSERM).

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tightly bound T-cell clusters: A new class of hyper-effector tumor killers. Cytokine Growth Factor Rev. 2025 Dec 13. Ma W, Pham J, Jamieson C. PMID: 41421921.
      View in: PubMed   Mentions:
    2. Harnessing the effector-to-regulatory T cell ratio to advance prognosis and precision therapy in pancreatic cancer. Crit Rev Oncol Hematol. 2025 Dec 09; 218:105076. Guo X, Zhang H, Yao L, Ma W. PMID: 41380868.
      View in: PubMed   Mentions:
    3. Harnessing IL-2 without feeding the enemy: modern strategies to overcome regulatory T cell expansion in cancer immunotherapy. Cancer Lett. 2025 Dec 28; 635:218109. Ma W, Jamieson C. PMID: 41183764.
      View in: PubMed   Mentions:
    4. Natural killers or natural regulators? Dual roles of NK cells in checkpoint immunotherapy. Cytokine Growth Factor Rev. 2025 Dec; 86:199-202. Ma W, Morris S, Jamieson C. PMID: 41202523.
      View in: PubMed   Mentions:
    5. Spatial immune landscapes of the human placenta: Biomarkers and therapeutic insights in pregnancy disorders. Biomed Pharmacother. 2025 Nov; 192:118688. Zhang N, Li J, Ma W, Zhou J. PMID: 41160999.
      View in: PubMed   Mentions:
    6. Fatal shots in cellular therapy: addressing early development pitfalls to improve clinical success. Cancer Lett. 2025 Dec 28; 635:218099. Yu B, Ma W. PMID: 41138898.
      View in: PubMed   Mentions:
    7. CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge. Oncol Res. 2025; 33(11):3375-3385. Guo X, Fu Y, Baran N, Ma W. PMID: 41179296; PMCID: PMC12573215.
      View in: PubMed   Mentions:
    8. Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeuticopportunities. Cytokine Growth Factor Rev. 2025 Dec; 86:71-82. Ma W, Morris S, Jamieson C. PMID: 41092888.
      View in: PubMed   Mentions:
    9. Developmental checkpoint targeting: Pre-TCR immunotherapy in leukemia and beyond. Cancer Lett. 2025 Sep 26; 218063. Ma W, Jamieson C. PMID: 41016678.
      View in: PubMed   Mentions:
    10. Chimeric Antigen Receptor-Macrophage Therapy Enters the Clinic: The First-in-Human Trial for HER2+ Solid Tumors. MedComm (2020). 2025 Sep; 6(9):e70374. Ma W, Jamieson C. PMID: 40895191; PMCID: PMC12390764.
      View in: PubMed   Mentions:
    11. Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics. Front Immunol. 2025; 16:1600261. Li M, Zhang Y, Yu D, Yu Y, Ma W. PMID: 40881677; PMCID: PMC12380822.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    12. Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy. World J Clin Oncol. 2025 Jul 24; 16(7):104959. Ma W, Baran N. PMID: 40741200; PMCID: PMC12304926.
      View in: PubMed   Mentions:
    13. Revisiting TAM polarization: beyond M1- and M2-type TAM toward clinical precision in macrophage-targeted therapy. Exp Mol Pathol. 2025 Sep; 143:104982. Wang Q, Ma W. PMID: 40664070.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    14. Haptens-based cancer immunotherapy: From biomarkers to translational advances. Biomed Pharmacother. 2025 Aug; 189:118240. Yu B, Ma W. PMID: 40513391.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    15. The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches. Front Immunol. 2025; 16:1595977. Guo X, Wang K, Liu Q, Baran N, Ma W. PMID: 40574831; PMCID: PMC12198146.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    16. Checkpoint kinase 1 as a promising target in colorectal cancer management. World J Clin Oncol. 2025 Apr 24; 16(4):104213. Ma W, Baran N. PMID: 40290692; PMCID: PMC12019260.
      View in: PubMed   Mentions:
    17. Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy. Biomed Pharmacother. 2024 Dec; 181:117753. Huang S, Xu J, Baran N, Ma W. PMID: 39667221.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    18. Cytokine modulation and immunoregulation of uterine NK cells in pregnancy disorders. Cytokine Growth Factor Rev. 2025 Feb; 81:40-53. Zhou J, Yan P, Ma W, Li J. PMID: 39603954.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    19. Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy. Cancer Lett. 2025 Feb 01; 610:217350. Yu B, Shao S, Ma W. PMID: 39581219.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    20. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development. Oncol Res. 2024; 32(12):1837-1850. Zheng W, Jiang D, Chen S, Wu M, Yan B, Zhai J, Shi Y, Xie B, Xie X, Hu K, Ma W. PMID: 39574477; PMCID: PMC11576958.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    21. Redefining the tumor microenvironment with emerging therapeutic strategies. Oncol Res. 2024; 32(11):1701-1708. Xu S, Li X, Ma W. PMID: 39449800; PMCID: PMC11497178.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    22. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis. Cytokine Growth Factor Rev. 2024 Oct; 79:29-38. Yu B, Ma W. PMID: 39191624.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    23. Role of LECT2 in exacerbating atopic dermatitis: insight from in vivo and in vitro models via NF-κB signaling pathway. Front Immunol. 2024; 15:1439367. Liu Z, Jiang X, Zhao K, Ruan H, Ma Y, Ma Y, Zhou Q, Zhang J, Sun X, Ma W, Xu S. PMID: 39206203; PMCID: PMC11349537.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    24. Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects. Biomed Pharmacother. 2024 Sep; 178:117285. Zhou Q, Shao S, Minev T, Ma W. PMID: 39128190.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    25. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024 Aug 05; 13(1):76. Li J, Chen P, Ma W. PMID: 39103972; PMCID: PMC11302330.
      View in: PubMed   Mentions: 20  
    26. CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Lett. 2024 Aug 10; 597:217072. Xu S, Ma Y, Jiang X, Wang Q, Ma W. PMID: 38885807.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    27. Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy. Cytokine Growth Factor Rev. 2024 04; 76:12-21. Xu S, Wang Q, Ma W. PMID: 38431507.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    28. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 2024 Apr; 115(4):1060-1072. Bao Y, Zhang D, Guo H, Ma W. PMID: 38308498; PMCID: PMC11007055.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    29. Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell Rep. 2024 02 27; 43(2):113704. Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Balaian L, Sasik R, Enlund S, Mark A, Ma W, Holm F, Fisch KM, Kuo DJ, Jamieson C, Jiang Q. PMID: 38265938; PMCID: PMC10962356.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    30. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front Immunol. 2023; 14:1332057. Chen Q, Jia G, Zhang X, Ma W. PMID: 38239350; PMCID: PMC10794487.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    31. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. Cancers (Basel). 2023 Dec 15; 15(24). Yao L, Wang Q, Ma W. PMID: 38136402; PMCID: PMC10742031.
      View in: PubMed   Mentions: 6  
    32. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2023; 32(1):49-60. Chen Q, Guo X, Ma W. PMID: 38188674; PMCID: PMC10767231.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    33. Game-changing insights on vertebral skeletal stem cells in bone metastasis and therapeutic horizons. Oncol Res. 2023; 32(1):95-98. Chen Q, Zhao X, Ma W. PMID: 38188672; PMCID: PMC10767245.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    34. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. Front Immunol. 2023; 14:1295684. Shao S, Miao H, Ma W. PMID: 38035068; PMCID: PMC10682717.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    35. Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements. Front Oncol. 2023; 13:1292211. Yao L, Chen J, Ma W. PMID: 37954074; PMCID: PMC10635515.
      View in: PubMed   Mentions: 7  
    36. Malignant A-to-I RNA editing by ADAR1 drives T-cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Res Sq. 2023 Jun 16. Rivera M, Zhang H, Pham J, Isquith J, Zhou QJ, Sasik R, Mark A, Ma W, Holm F, Fisch KM, Kuo DJ, Jamieson C, Jiang Q. PMID: 37398458; PMCID: PMC10312963.
      View in: PubMed   Mentions:
    37. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine. 2023 03 17; 41(12):2073-2083. Lu L, Ma W, Johnson CH, Khan SA, Irwin ML, Pusztai L. PMID: 36813666; PMCID: PMC10064809.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    38. Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell Stem Cell. 2023 03 02; 30(3):250-263.e6. Crews LA, Ma W, Ladel L, Pham J, Balaian L, Steel SK, Mondala PK, Diep RH, Wu CN, Mason CN, van der Werf I, Oliver I, Reynoso E, Pineda G, Whisenant TC, Wentworth P, La Clair JJ, Jiang Q, Burkart MD, Jamieson CHM. PMID: 36803553; PMCID: PMC10134781.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    39. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers (Basel). 2022 Dec 03; 14(23). Chen Q, Lu L, Ma W. PMID: 36497465; PMCID: PMC9739567.
      View in: PubMed   Mentions: 22  
    40. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Curr Oncol. 2022 07 12; 29(7):4902-4913. Yao L, Jia G, Lu L, Ma W. PMID: 35877249; PMCID: PMC9320700.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    41. Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. Heliyon. 2022 Apr; 8(4):e09302. Yao L, Lu L, Ma W. PMID: 35497026; PMCID: PMC9040416.
      View in: PubMed   Mentions: 8  
    42. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Sci Adv. 2021 08; 7(33). Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG, Kim CH, Young TS. PMID: 34380625; PMCID: PMC8357232.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    43. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Rep. 2021 01 26; 34(4):108670. Jiang Q, Isquith J, Ladel L, Mark A, Holm F, Mason C, He Y, Mondala P, Oliver I, Pham J, Ma W, Reynoso E, Ali S, Morris IJ, Diep R, Nasamran C, Xu G, Sasik R, Rosenthal SB, Birmingham A, Coso S, Pineda G, Crews L, Donohoe ME, Venter JC, Whisenant T, Mesa RA, Alexandrov LB, Fisch KM, Jamieson C. PMID: 33503434; PMCID: PMC8477897.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    44. Novel Survivin Peptides Screened With Computer Algorithm Induce Cytotoxic T Lymphocytes With Higher Cytotoxic Efficiency to Cancer Cells. Front Mol Biosci. 2020; 7:570003. Chen Q, Jia G, Zhao X, Bao Y, Zhang Y, Ozkan C, Minev B, Ma W. PMID: 33102521; PMCID: PMC7496070.
      View in: PubMed   Mentions: 5  
    45. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Int Immunopharmacol. 2020 Aug; 85:106628. Yao L, Jia G, Lu L, Bao Y, Ma W. PMID: 32474388.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    46. Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses. Drug Deliv Transl Res. 2019 12; 9(6):1095-1105. Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, Minev B, Ma W. PMID: 31228097.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    47. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223. Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. PMID: 31427721; PMCID: PMC7297141.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    48. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer. 2019 Apr 25; 19(1):387. Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. PMID: 31023256; PMCID: PMC6482542.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    49. Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. Cancer Cell. 2019 01 14; 35(1):81-94.e7. Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N, Reynoso E, Chau J, Leu H, Lazzari E, Melese E, Ma W, Fang R, Minden M, Morris S, Ren B, Pineda G, Holm F, Jamieson C. PMID: 30612940; PMCID: PMC6333511.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    50. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clin Transl Oncol. 2019 Apr; 21(4):433-442. Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. PMID: 30218306.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    51. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Immunology. 2017 11; 152(3):462-471. Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. PMID: 28664991; PMCID: PMC5629434.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    52. Metastasis-Associated Protein 1 Is Involved in Angiogenesis after Transarterial Chemoembolization Treatment. Biomed Res Int. 2017; 2017:6757898. Xue T, Feng W, Yu H, Zhu M, Fei M, Bao Y, Wang X, Ma W, Lv G, Guan J, Chen S. PMID: 28589145; PMCID: PMC5447282.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    53. IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. Int Immunopharmacol. 2017 Jun; 47:159-165. Shao S, Risch E, Burner D, Lu L, Minev B, Ma W. PMID: 28410529.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    54. Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies. Int J Mol Sci. 2015 Aug 18; 16(8):19518-36. Li H, Tsui TY, Ma W. PMID: 26295227; PMCID: PMC4581311.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    55. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Res Treat. 2015 Jun; 151(3):491-500. Lu L, Zeng H, Gu X, Ma W. PMID: 25957595.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    56. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med. 2014 Oct 03; 12:275. Godebu E, Muldong M, Strasner A, Wu CN, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, Jamieson CA. PMID: 25278011; PMCID: PMC4192441.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    57. Intracellular delivery of tumor antigenic peptides in biodegradable-polymer adjuvant for enhancing cancer immunotherapy. Curr Med Chem. 2014; 21(21):2357-66. Li H, Ma W. PMID: 25030301.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    58. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013 May; 3(5):564-77. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. PMID: 23471820; PMCID: PMC3651770.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    59. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 07; 12(3):316-28. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. PMID: 23333150; PMCID: PMC3968867.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansCells
    60. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012 Aug 14; 22(2):209-21. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT. PMID: 22897851; PMCID: PMC3422504.
      View in: PubMed   Mentions: 193     Fields:    Translation:HumansCells
    61. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One. 2012; 7(6):e39725. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. PMID: 22768113; PMCID: PMC3387267.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    62. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 2012; 7:1475-87. Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T, Minev B. PMID: 22619507; PMCID: PMC3356185.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    63. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med. 2011 Mar 31; 9:34. Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M, Hayden M, Schroter S, Carrier E, Messmer D, Kumar V, Minev B. PMID: 21450109; PMCID: PMC3078865.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    64. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv Transl Res. 2011 Feb; 1(1):43-52. Sharma B, Ma W, Adjei IM, Panyam J, Dimitrijevic S, Labhasetwar V. PMID: 22553503; PMCID: PMC3339849.
      View in: PubMed   Mentions: 15     Fields:    
    65. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Chut T, Soiffer R, Mitrovich RC, Lowy I, Ball ED. PMID: 20713164; PMCID: PMC2992836.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    66. Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine. 2010 Oct; 6(5):651-61. Clawson C, Huang CT, Futalan D, Seible DM, Saenz R, Larsson M, Ma W, Minev B, Zhang F, Ozkan M, Ozkan C, Esener S, Messmer D. PMID: 20348031; PMCID: PMC2947606.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    67. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. PMID: 20124220; PMCID: PMC2854430.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    68. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour. Eur J Clin Invest. 2008 Dec; 38(12):931-8. Liu WG, Gu WZ, Zhou YB, Tang HF, Li MJ, Ma WX. PMID: 19021718.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):566-575. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR. PMID: 17255279; PMCID: PMC4030524.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    70. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol. 2006 Nov; 18(11):1563-73. Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B, Schmidt-Wolf IG, Tracey KJ, Chiorazzi N, Messmer D. PMID: 16966494.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    71. A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy. Immunol Lett. 2005 Oct 15; 101(1):71-80. Huang C, Yu H, Wang Q, Yang G, Ma W, Xia D, Chen X, Yi P, Shen F, Zheng H, Cao X. PMID: 15908014.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    72. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study. Clin Oncol (R Coll Radiol). 2005 Jun; 17(4):258-63. Ma W, Deng Y, Zhou L. PMID: 15997921.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect. Cancer. 2005 Apr 01; 103(7):1519-28. Yi P, Yu H, Ma W, Wang Q, Minev BR. PMID: 15739200.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    74. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004 Nov 01; 112(2):335-40. Sahoo SK, Ma W, Labhasetwar V. PMID: 15352049.
      View in: PubMed   Mentions: 74     Fields:    Translation:Animals
    75. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004 May; 24(3):294-301. Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. PMID: 15114060.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    76. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci. 2004 Feb; 95(2):160-7. Huang C, Yu H, Wang Q, Ma W, Xia D, Yi P, Zhang L, Cao X. PMID: 14965367; PMCID: PMC11159597.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    77. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein. Cancer Immunol Immunother. 2004 Feb; 53(2):118-24. Ma W, Yu H, Wang Q, Bao J, Yan J, Jin H. PMID: 14574492; PMCID: PMC11032846.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    78. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003 Sep 19; 92(1-2):173-87. Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V. PMID: 14499195.
      View in: PubMed   Mentions: 109     Fields:    Translation:Animals
    Wenxue's Networks
    Concepts (322)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (35)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California